Oncology FISH Analysis - AML FISH Panel

Clinical Use

Use

Oncology FISH Analysis - AML is a Fluorescence In Situ Hybridization (FISH) test designed to detect common chromosomal abnormalities associated with acute myeloid leukemia (AML) that are of diagnostic and prognostic significance. AML predominantly affects adults and originates from undifferentiated white blood cells in the bone marrow, often impacting multiple organs. This assay detects various abnormalities, including chromosomal gains and translocations, which can significantly influence treatment decisions and prognoses. Results need to be interpreted alongside clinical context to ensure accurate diagnosis and management.

Special Instructions

This assay requires specific specimen conditions and timely shipping to ensure viability. Proper preparation adherence, including the use of designated containers and handling instructions, is crucial for accurate results. Testing indications include suspected AML diagnoses, follow-up on confirmed cases, and composition of effective treatment plans. The analysis is integral for guiding clinical decisions.

Limitations

The panel is limited to testing for specified rearrangements associated with the loci indicated by each probe. It does not evaluate rearrangements involving other chromosomes that may affect the outcome. Moreover, results should be interpreted considering clinical and pathological data and cannot solely confirm a diagnosis of AML. The complexity of AML and variability in chromosomal abnormalities may lead to instances of false negatives if the responsible markers are not included in this analysis.

Test Details